Inspire Medical Systems Inc. stocks have been trading up by 7.16 percent following upbeat coverage of its sleep apnea device.
Click Here for a Millionaire's POV on Trading INSP
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Stifel raised its price target on Inspire Medical Systems to $80 from $75 and reiterated a Buy rating after Q2 results beat consensus and 2026 guidance was nudged higher.
- The Stifel analyst cited favorable risk/reward in Inspire Medical Systems shares and pointed to several potential upcoming catalysts.
- Management will present at the Wells Fargo 21st Annual Healthcare Conference, with the webcast offering another look at the story.
- A recent Form 4 flagged a change in insider beneficial ownership, though no size, type, or price data was disclosed.
Weekly Update Sep 07 – Sep 11, 2026: On Sunday, September 13, 2026 Inspire Medical Systems Inc. stock [NYSE: INSP] is trending up by 7.16%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Inspire Medical Systems occupies a strong niche leadership position in hypoglossal nerve stimulation for obstructive sleep apnea, with 2026 Q2 revenue at ~$201M and annualized sales near $900M, growing ~20%+ with an 86% gross margin. Operating leverage remains underdeveloped: EBIT margin is low single digits and quarterly operating income was slightly negative, with GAAP profitability flattered by high stock-based compensation. Balance sheet quality is excellent, with minimal leverage (D/E ~0.04), robust liquidity (current ratio 8.6), and strong ROIC in the mid-teens.
The stock’s recent price action shows a sharp, persistent uptrend: a clean progression from $62 to $73 over four sessions, with each day closing near the high and no meaningful intraday reversals, confirming aggressive dip-buying. Five‑minute candles indicate orderly consolidations rather than blow‑off spikes, suggesting institutional accumulation rather than speculative churn. The first key trading level is $68–69, the prior breakout zone; that area is now firm support. Above, near‑term resistance sits at $75, where profit‑taking is likely on the initial test.
More Breaking News
- RKT Stock Draws Traders As Rocket Bets On VantageScore
- Rogers Corporation Stock Jumps As Traders Eye 2026 Investor Day
- Accenture Stock Climbs As AI Deals And New Units Drive Momentum
- UiPath (PATH) Stock Faces Cautious Wall Street As AI Push Accelerates
Fundamentally and sentiment-wise, INSP now screens better than most healthcare and med‑tech peers: high structural growth, superior gross margins, and a clean balance sheet justify a premium multiple even as the P/E compresses toward more sustainable levels. Stifel’s target hike to $80 and guidance raise reinforce institutional confidence, while conference visibility and ongoing adoption expand the TAM. I see a 6–12 month upside target of $80–85, with technical support at $68 and secondary support near $62.
Quick Financial Overview
Inspire Medical Systems Inc. (INSP) has seen a sharp, momentum-style move on the tape. Weekly data show the stock climbing from $62.14 to $73 over just a few sessions, a fast gain that confirms strong demand after the Q2 beat and the Stifel price target increase to $80 on 2026/09/11. Intraday, a single wide 5‑minute bar shows price ripping from a $69.88 open to a $74.95 high and closing at $73, signaling aggressive buying and little intraday giveback.
Under the hood, the business profile supports this bullish interest. Inspire Medical Systems generated roughly $912M in trailing revenue, with an 86.1% gross margin and positive EBITDA margin near 9%. Revenue growth has been robust, with three‑year and five‑year growth rates of 19.54% and 38.69%, respectively. For Q2 2026, total revenue was about $200.6M, with net income essentially breakeven at $0.01 per share, reflecting heavy spend in selling and administrative lines but still positive operating cash flow.
The balance sheet gives traders a cushion. Total assets sit near $926M, equity around $826M, and total liabilities only about $100M, driving a current ratio of 8.6 and very low debt usage (total debt‑to‑equity of 0.04). Cash and short‑term investments exceed $320M, while free cash flow in the latest quarter was about $14.1M. Valuation metrics such as a price‑to‑sales near 2.35 and P/E around 16.1 suggest the market is paying a growth multiple, but not an extreme one when lined up against the company’s return on equity near 18% on a last‑twelve‑month basis.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.